Slide 1: 2015 Preliminary results, 2016 Targets
2015 Preliminary results 2016 Targets CONFERENCE CALL – 11 FEBRUARY 2016
Slide 2: Full year 2015 highlights
Full year 2015 highlights • Revenue € 1,047.7 million, up 6.1% • Operating income (EBIT) € 278.5 million or 26.6% of sales, up 20.6% • Net income € 198.8 million or 19.0% of sales, up 23.3% • Net debt € 88.7 million, a reduction of € 97.3 million as compared to year‐end 2014 after payment of dividen
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 60.2% of revenue (million Euro) 2015 2014 Change % Zanidip® (lercanidipine) 115.7 109.2 5.9 Zanipress® (lercanidipine+enalapril) 65.7 61.3 7.2 Urorec® (silodosin) 68.3 59.1 15.6 Livazo® (pitavastatin) 28.4 25.5 11.4
Slide 4: A diversified product portfolio
A diversified product portfolio Other corporate products 13.8% Drugs for rare diseases 14.6% Livazo® 2.7% Urorec® 6.5% Zanipress® 6.3% OTC 16.9% Zanidip® 11.0% Subsidiaries’ local product portfolios 23.6% Pharmaceutical chemicals 3.4% Methadone ‐ France 3% Other revenue 1.2% Ortoton® (methocarbamol)
Slide 5: Composition of revenue by geography
Composition of revenue by geography Solid volume growth (million Euro) 2015 2014 Change % Italy 204.8 212.3 (3.5) France 110.6 111.0 (0.4) Germany 94.8 84.6 11.9 U.S.A. 82.1 56.8 44.6 Turkey 74.1 68.0 8.9 Russia, other CIS countries and Ukraine 72.4 81.3 (11.0) Spain 72.0 68.2 5.6 North Africa 43.7
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical revenue Other international sales 15.7% (sales to licensees and exports) Italy 20.2% Other W. Europe 2.8% Other CEE 3.1% Portugal 3.9% France 10.9% North Africa 4.3% Spain 7.1% Germany 9.4% Russia, other CIS and Ukraine 7.2% Turkey 7.3% U.S.A. 8.1% Data: Full
Slide 7: Full year 2015 results: Further margin growth
Full year 2015 results Further margin growth (million Euro) 2015 2014 Change % Revenue 1,047.7 987.4 6.1 Gross Profit 712.5 660.3 7.9 as % of revenue 68.0 66.9 SG&A Expenses 352.2 340.1 3.5 as % of revenue 33.6 34.5 R&D Expenses 76.7 85.3 (10.0) as % of revenue 7.3 8.6 Other Income (Expense), net (5
Slide 8: Full year 2015 results: Operating segments
Full year 2015 results Operating segments Revenue EBIT Treatments for rare diseases 14.6% Treatments for rare diseases 22.6% Primary & specialty care Primary & specialty care 85.4% 77.4% EBIT margin on sales: Treatments for rare diseases, 41,1% Primary & Specialty care, 24.1% 8
Slide 9: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 31 Dec 2015 31 Dec 2014 Change Cash and short‐term financial 225.5 137.0 88.5 investments Bank overdrafts and short‐term loans (9.8) (8.6) (1.2) Loans – due within one year (34.5) (28.3) (6.2) Loans – due after one year (269.9) (286.2) 16.3
Slide 10: Financial projections: 2016 targets
Financial projections 2016 targets 2015 2016 (million Euro) Actual Targets Revenue 1,047.7 1,070 – 1,100 Operating income 278.5 290 – 300 (EBIT) Net Income 198.8 205 ‐ 215 10
Slide 11: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan